Cargando…

Cost-Effectiveness of Cardiac Rehabilitation in Patients with Coronary Artery Disease: A Meta-Analysis

BACKGROUND: Medical costs associated with cardiovascular disease are increasing considerably worldwide; therefore, an efficacious, cost-effective therapy which allows the effective use of medical resources is vital. There have been few economic evaluations of cardiac rehabilitation (CR), especially...

Descripción completa

Detalles Bibliográficos
Autores principales: Takura, Tomoyuki, Ebata-Kogure, Nozomi, Goto, Yoichi, Kohzuki, Masahiro, Nagayama, Masatoshi, Oikawa, Keiko, Koyama, Teruyuki, Itoh, Haruki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6589196/
https://www.ncbi.nlm.nih.gov/pubmed/31275640
http://dx.doi.org/10.1155/2019/1840894
_version_ 1783429350703497216
author Takura, Tomoyuki
Ebata-Kogure, Nozomi
Goto, Yoichi
Kohzuki, Masahiro
Nagayama, Masatoshi
Oikawa, Keiko
Koyama, Teruyuki
Itoh, Haruki
author_facet Takura, Tomoyuki
Ebata-Kogure, Nozomi
Goto, Yoichi
Kohzuki, Masahiro
Nagayama, Masatoshi
Oikawa, Keiko
Koyama, Teruyuki
Itoh, Haruki
author_sort Takura, Tomoyuki
collection PubMed
description BACKGROUND: Medical costs associated with cardiovascular disease are increasing considerably worldwide; therefore, an efficacious, cost-effective therapy which allows the effective use of medical resources is vital. There have been few economic evaluations of cardiac rehabilitation (CR), especially meta-analyses of medical cost versus patient outcome. METHODS: The target population in this meta-analysis included convalescent and comprehensive CR patients with coronary artery disease (CAD), the status most commonly observed postmyocardial infarction (MI). Here, we evaluated medical costs, quality-adjusted life year (QALY), cost-effectiveness, mortality, and life year (LY). Regarding cost-effectiveness analysis, we analyzed medical costs per QALY, medical costs per LY, and the incremental cost-utility ratio (ICUR). We then examined the differences in effects for the 2 treatment arms (CR vs. usual care (UC)) using the risk ratio (RR) and standardized mean difference (SMD). RESULTS: We reviewed 59 studies and identified 5 studies that matched our selection criteria. In total, 122,485 patients were included in the analysis. Meta-analysis results revealed that the CR arm significantly improved QALY (SMD: −1.78; 95% confidence interval (CI): −2.69, −0.87) compared with UC. Although medical costs tended to be higher in the CR arm compared to the UC arm (SMD: 0.02; 95% CI: −0.08, 0.13), cost/QALY was significantly improved in the CR arm compared with the UC arm (SMD: −0.31; 95% CI: −0.53, −0.09). The ICURs for the studies (4 RCTs and 1 model analysis) were as follows: −48,327.6 USD/QALY; −5,193.8 USD/QALY (dominant, CR is cheaper and more effective than UC); and 4,048.0 USD/QALY, 17,209.4 USD/QALY, and 26,888.7 USD/QALY (<50,000 USD/QALY, CR is costlier but more effective than UC), respectively. Therefore, there were 2 dominant and 3 effective results. CONCLUSIONS: While there are some limitations, primarily regarding data sources, our results suggest that CR is potentially cost-effective.
format Online
Article
Text
id pubmed-6589196
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-65891962019-07-04 Cost-Effectiveness of Cardiac Rehabilitation in Patients with Coronary Artery Disease: A Meta-Analysis Takura, Tomoyuki Ebata-Kogure, Nozomi Goto, Yoichi Kohzuki, Masahiro Nagayama, Masatoshi Oikawa, Keiko Koyama, Teruyuki Itoh, Haruki Cardiol Res Pract Review Article BACKGROUND: Medical costs associated with cardiovascular disease are increasing considerably worldwide; therefore, an efficacious, cost-effective therapy which allows the effective use of medical resources is vital. There have been few economic evaluations of cardiac rehabilitation (CR), especially meta-analyses of medical cost versus patient outcome. METHODS: The target population in this meta-analysis included convalescent and comprehensive CR patients with coronary artery disease (CAD), the status most commonly observed postmyocardial infarction (MI). Here, we evaluated medical costs, quality-adjusted life year (QALY), cost-effectiveness, mortality, and life year (LY). Regarding cost-effectiveness analysis, we analyzed medical costs per QALY, medical costs per LY, and the incremental cost-utility ratio (ICUR). We then examined the differences in effects for the 2 treatment arms (CR vs. usual care (UC)) using the risk ratio (RR) and standardized mean difference (SMD). RESULTS: We reviewed 59 studies and identified 5 studies that matched our selection criteria. In total, 122,485 patients were included in the analysis. Meta-analysis results revealed that the CR arm significantly improved QALY (SMD: −1.78; 95% confidence interval (CI): −2.69, −0.87) compared with UC. Although medical costs tended to be higher in the CR arm compared to the UC arm (SMD: 0.02; 95% CI: −0.08, 0.13), cost/QALY was significantly improved in the CR arm compared with the UC arm (SMD: −0.31; 95% CI: −0.53, −0.09). The ICURs for the studies (4 RCTs and 1 model analysis) were as follows: −48,327.6 USD/QALY; −5,193.8 USD/QALY (dominant, CR is cheaper and more effective than UC); and 4,048.0 USD/QALY, 17,209.4 USD/QALY, and 26,888.7 USD/QALY (<50,000 USD/QALY, CR is costlier but more effective than UC), respectively. Therefore, there were 2 dominant and 3 effective results. CONCLUSIONS: While there are some limitations, primarily regarding data sources, our results suggest that CR is potentially cost-effective. Hindawi 2019-06-04 /pmc/articles/PMC6589196/ /pubmed/31275640 http://dx.doi.org/10.1155/2019/1840894 Text en Copyright © 2019 Tomoyuki Takura et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Takura, Tomoyuki
Ebata-Kogure, Nozomi
Goto, Yoichi
Kohzuki, Masahiro
Nagayama, Masatoshi
Oikawa, Keiko
Koyama, Teruyuki
Itoh, Haruki
Cost-Effectiveness of Cardiac Rehabilitation in Patients with Coronary Artery Disease: A Meta-Analysis
title Cost-Effectiveness of Cardiac Rehabilitation in Patients with Coronary Artery Disease: A Meta-Analysis
title_full Cost-Effectiveness of Cardiac Rehabilitation in Patients with Coronary Artery Disease: A Meta-Analysis
title_fullStr Cost-Effectiveness of Cardiac Rehabilitation in Patients with Coronary Artery Disease: A Meta-Analysis
title_full_unstemmed Cost-Effectiveness of Cardiac Rehabilitation in Patients with Coronary Artery Disease: A Meta-Analysis
title_short Cost-Effectiveness of Cardiac Rehabilitation in Patients with Coronary Artery Disease: A Meta-Analysis
title_sort cost-effectiveness of cardiac rehabilitation in patients with coronary artery disease: a meta-analysis
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6589196/
https://www.ncbi.nlm.nih.gov/pubmed/31275640
http://dx.doi.org/10.1155/2019/1840894
work_keys_str_mv AT takuratomoyuki costeffectivenessofcardiacrehabilitationinpatientswithcoronaryarterydiseaseametaanalysis
AT ebatakogurenozomi costeffectivenessofcardiacrehabilitationinpatientswithcoronaryarterydiseaseametaanalysis
AT gotoyoichi costeffectivenessofcardiacrehabilitationinpatientswithcoronaryarterydiseaseametaanalysis
AT kohzukimasahiro costeffectivenessofcardiacrehabilitationinpatientswithcoronaryarterydiseaseametaanalysis
AT nagayamamasatoshi costeffectivenessofcardiacrehabilitationinpatientswithcoronaryarterydiseaseametaanalysis
AT oikawakeiko costeffectivenessofcardiacrehabilitationinpatientswithcoronaryarterydiseaseametaanalysis
AT koyamateruyuki costeffectivenessofcardiacrehabilitationinpatientswithcoronaryarterydiseaseametaanalysis
AT itohharuki costeffectivenessofcardiacrehabilitationinpatientswithcoronaryarterydiseaseametaanalysis